Juventas tests gene therapy on wounds in Phase II trial

Story excerpt provided by Crain’s Cleveland Business.

Written by Chuck Soder.

Juventas has started a new clinical trial to test whether the company’s gene therapy drug could be used to heal wounds that could cause someone to lose a leg. The Cleveland company has enrolled the first patient in the Phase II trial, which will treat people who suffer from wounds caused by advanced peripheral artery disease — a disease that restricts blood flow to the limbs, which causes pain and can sometimes lead to amputation.

Click here to read the complete article.

Originally published February 4, 2016.